2024
Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
Faust J, Renton B, Bongiovanni T, Chen A, Sheares K, Du C, Essien U, Fuentes-Afflick E, Haywood T, Khera R, King T, Li S, Lin Z, Lu Y, Marshall A, Ndumele C, Opara I, Loarte-Rodriguez T, Sawano M, Taparra K, Taylor H, Watson K, Yancy C, Krumholz H. Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2438918. PMID: 39392630, DOI: 10.1001/jamanetworkopen.2024.38918.Peer-Reviewed Original ResearchConceptsCOVID-19 public health emergencyNon-HispanicPublic health emergencyOther Pacific IslanderExcess mortalityAlaska NativesUS populationExcess deathsRates of excess mortalityCross-sectional study analyzed dataYears of potential lifeMortality relative riskNon-Hispanic whitesCross-sectional studyPacific IslandersStudy analyzed dataAll-cause mortalityEthnic groupsMortality disparitiesMortality ratioTotal populationDeath certificatesEthnic disparitiesMain OutcomesDecedent age
2022
Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism
Sadeghipour P, Jenab Y, Moosavi J, Hosseini K, Mohebbi B, Hosseinsabet A, Chatterjee S, Pouraliakbar H, Shirani S, Shishehbor MH, Alizadehasl A, Farrashi M, Rezvani MA, Rafiee F, Jalali A, Rashedi S, Shafe O, Giri J, Monreal M, Jimenez D, Lang I, Maleki M, Goldhaber SZ, Krumholz HM, Piazza G, Bikdeli B. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism. JAMA Cardiology 2022, 7: 1189-1197. PMID: 36260302, PMCID: PMC9582964, DOI: 10.1001/jamacardio.2022.3591.Peer-Reviewed Original ResearchConceptsConventional catheter-directed thrombolysisRV/LV ratioRisk pulmonary embolismCatheter-directed thrombolysisProportion of patientsPulmonary embolismLV ratioMajor bleedingPrimary outcomeRight ventricleClinical trialsIntermediate-high risk pulmonary embolismDefinitive clinical outcome trialsMain safety outcomeMajor gastrointestinal bleedingRV/LVClinical events committeeClinical outcome trialsLarge cardiovascular centresCause mortalityEfficacy outcomesGastrointestinal bleedingMonotherapy groupOutcome trialsSecondary outcomesChanges in Emergency Department Arrival Times for Acute Myocardial Infarction During the COVID-19 Pandemic Suggest Delays in Care Seeking
Janke AT, Gettel CJ, Haimovich A, Kocher KE, Krumholz HM, Venkatesh AK. Changes in Emergency Department Arrival Times for Acute Myocardial Infarction During the COVID-19 Pandemic Suggest Delays in Care Seeking. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008402. PMID: 35105172, PMCID: PMC8833230, DOI: 10.1161/circoutcomes.121.008402.Peer-Reviewed Original ResearchPhysical Activity Among Patients With Intracardiac Remote Monitoring Devices Before, During, and After COVID-19–Related Restrictions
Lu Y, Jones PW, Murugiah K, Caraballo C, Massey DS, Mahajan S, Ahmed R, Bader EM, Krumholz HM. Physical Activity Among Patients With Intracardiac Remote Monitoring Devices Before, During, and After COVID-19–Related Restrictions. Journal Of The American College Of Cardiology 2022, 79: 309-310. PMID: 35057917, PMCID: PMC8763290, DOI: 10.1016/j.jacc.2021.11.010.Peer-Reviewed Original Research
2021
Tracking Self-reported Symptoms and Medical Conditions on Social Media During the COVID-19 Pandemic: Infodemiological Study
Ding Q, Massey D, Huang C, Grady CB, Lu Y, Cohen A, Matzner P, Mahajan S, Caraballo C, Kumar N, Xue Y, Dreyer R, Roy B, Krumholz HM. Tracking Self-reported Symptoms and Medical Conditions on Social Media During the COVID-19 Pandemic: Infodemiological Study. JMIR Public Health And Surveillance 2021, 7: e29413. PMID: 34517338, PMCID: PMC8480398, DOI: 10.2196/29413.Peer-Reviewed Original ResearchEngagement With COVID-19 Public Health Measures in the United States: A Cross-sectional Social Media Analysis from June to November 2020
Massey D, Huang C, Lu Y, Cohen A, Oren Y, Moed T, Matzner P, Mahajan S, Caraballo C, Kumar N, Xue Y, Ding Q, Dreyer R, Roy B, Krumholz H. Engagement With COVID-19 Public Health Measures in the United States: A Cross-sectional Social Media Analysis from June to November 2020. Journal Of Medical Internet Research 2021, 23: e26655. PMID: 34086593, PMCID: PMC8218897, DOI: 10.2196/26655.Peer-Reviewed Original ResearchIntermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial
Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, Riahi T, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Amin A, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Dobesh PP, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Stone GW, Lip GYH, Krumholz H, Goldhaber SZ, Sadeghipour P. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis And Haemostasis 2021, 122: 131-141. PMID: 33865239, DOI: 10.1055/a-1485-2372.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationExtracorporeal membrane oxygenationProphylactic anticoagulationIntermediate doseEfficacy outcomesArterial thrombosisCOVID-19Hospital discharge statusMain safety outcomeProphylactic antithrombotic therapyComposite of deathCritically Ill PatientsPrimary efficacy outcomeStandard-dose groupIntermediate-dose groupIntensive care unitCoronavirus disease 2019Cause deathMajor bleedingModified intentionOpen labelAntithrombotic therapyExtrapulmonary manifestationsHospital dischargeThrombotic complications
2020
Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov
Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. JAMA Internal Medicine 2020, 180: 1398-1400. PMID: 32730617, PMCID: PMC7385669, DOI: 10.1001/jamainternmed.2020.2904.Peer-Reviewed Original ResearchThe American College of Cardiology Roundtable on Research in the Era of COVID-19
Krumholz HM, Januzzi JL. The American College of Cardiology Roundtable on Research in the Era of COVID-19. Journal Of The American College Of Cardiology 2020, 76: 1263-1265. PMID: 32883419, PMCID: PMC7458524, DOI: 10.1016/j.jacc.2020.08.006.Peer-Reviewed Original ResearchStroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic
Jasne AS, Chojecka P, Maran I, Mageid R, Eldokmak M, Zhang Q, Nystrom K, Vlieks K, Askenase M, Petersen N, Falcone GJ, Wira CR, Lleva P, Zeevi N, Narula R, Amin H, Navaratnam D, Loomis C, Hwang DY, Schindler J, Hebert R, Matouk C, Krumholz HM, Spudich S, Sheth KN, Sansing LH, Sharma R. Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. Stroke 2020, 51: 2664-2673. PMID: 32755347, PMCID: PMC7446978, DOI: 10.1161/str.0000000000000347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBetacoronavirusBrain IschemiaCohort StudiesComorbidityConnecticutCoronary Artery DiseaseCoronavirus InfectionsCOVID-19DyslipidemiasEmergency Medical ServicesEthnicityFemaleHumansHypertensionIncomeInsurance, HealthIntracranial HemorrhagesMaleMedically UninsuredMiddle AgedOutcome and Process Assessment, Health CarePandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Severity of Illness IndexStrokeSubstance-Related DisordersTelemedicineThrombectomyThrombolytic TherapyTime-to-TreatmentConceptsComprehensive stroke centerStroke codePatient characteristicsStroke severityStroke code patientsHistory of hypertensionStroke-like symptomsCoronary artery diseaseCoronavirus disease 2019 (COVID-19) pandemicPatient-level dataLower median household incomePublic health initiativesDisease 2019 pandemicCOVID-19 pandemicRace/ethnicityCode patientsHospital presentationPublic health insuranceRankin ScaleStroke centersArtery diseaseReperfusion timeStroke symptomsEarly outcomesConnecticut hospitalsExtrapulmonary manifestations of COVID-19
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Extrapulmonary manifestations of COVID-19. Nature Medicine 2020, 26: 1017-1032. PMID: 32651579, DOI: 10.1038/s41591-020-0968-3.Peer-Reviewed Original ResearchConceptsExtrapulmonary manifestationsCOVID-19Acute kidney injuryAcute coronary syndromeSpectrum of manifestationsCoronavirus SARS-CoV-2SARS-CoV-2Coronary syndromeGastrointestinal symptomsKidney injuryOcular symptomsThrombotic complicationsHepatocellular injuryEndothelial damageMyocardial dysfunctionDermatologic complicationsNeurologic illnessRespiratory pathologyImmune responseExtrapulmonary tissuesTherapeutic strategiesEntry receptorTissue damageOrgan systemsInjuryQuality of primary health care in China: challenges and recommendations
Li X, Krumholz HM, Yip W, Cheng KK, De Maeseneer J, Meng Q, Mossialos E, Li C, Lu J, Su M, Zhang Q, Xu DR, Li L, Normand ST, Peto R, Li J, Wang Z, Yan H, Gao R, Chunharas S, Gao X, Guerra R, Ji H, Ke Y, Pan Z, Wu X, Xiao S, Xie X, Zhang Y, Zhu J, Zhu S, Hu S. Quality of primary health care in China: challenges and recommendations. The Lancet 2020, 395: 1802-1812. PMID: 32505251, PMCID: PMC7272159, DOI: 10.1016/s0140-6736(20)30122-7.Peer-Reviewed Original ResearchConceptsPrimary health care systemHealth care systemPrimary health carePublic health servicesClinical careHealth servicesPrimary health care physiciansPrimary health care practitionersPrimary health care institutionsBasic public health servicesHealth care physiciansHealth careCoronavirus disease 2019Entire health care systemHealth care practitionersHigh-value careLearning health systemChronic diseasesDisease 2019Health care institutionsInfectious diseasesHealth systemCare systemCareSuboptimal educationAn Evaluation of the Vulnerable Physician Workforce in the USA During the Coronavirus Disease-19 Pandemic
Khera R, Dhingra LS, Jain S, Krumholz HM. An Evaluation of the Vulnerable Physician Workforce in the USA During the Coronavirus Disease-19 Pandemic. Journal Of General Internal Medicine 2020, 35: 3114-3116. PMID: 32495101, PMCID: PMC7269617, DOI: 10.1007/s11606-020-05854-7.Peer-Reviewed Original ResearchPharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Group T. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis And Haemostasis 2020, 120: 1004-1024. PMID: 32473596, PMCID: PMC7516364, DOI: 10.1055/s-0040-1713152.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Subgroup of patientsCOVID-19 patientsFuture prospective studiesManagement of thrombosisSyndrome coronavirus 2Coronavirus disease 2019Mechanism of actionViral illnessThrombotic eventsRandomized trialsProspective studyAntithrombotic effectCoronavirus 2Antithrombotic agentsAntithrombotic drugsAntiviral effectDisease 2019Thrombotic diseaseAntithrombotic propertiesDosing approachWorldwide pandemicAgile Health Care Analytics: Enabling Real-Time Disease Surveillance With a Computational Health Platform
Schulz WL, Durant T, Torre CJ, Hsiao AL, Krumholz HM. Agile Health Care Analytics: Enabling Real-Time Disease Surveillance With a Computational Health Platform. Journal Of Medical Internet Research 2020, 22: e18707. PMID: 32442130, PMCID: PMC7257473, DOI: 10.2196/18707.Peer-Reviewed Original ResearchConceptsReal-time dataHealth information technologyReal-world dataHealth platformInformation technologyCombination of technologiesReal timeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Timely informationRespiratory syndrome coronavirus 2PlatformRespiratory tract infectionsSyndrome coronavirus 2Health care systemTract infectionsCoronavirus disease (COVID-19) outbreakIncident casesCoronavirus 2Novel applicationTechnologyAnalyticsHealth systemCare systemSpecific pathogensCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunctionCardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. Journal Of The American College Of Cardiology 2020, 75: 2352-2371. PMID: 32201335, PMCID: PMC7198856, DOI: 10.1016/j.jacc.2020.03.031.Peer-Reviewed Original ResearchConceptsHealth care workersCare workersCardiovascular ConsiderationsCardiovascular careCOVID-19Severe acute respiratory syndrome coronavirus 2Pre-existing cardiovascular diseaseAcute respiratory syndrome coronavirus 2Health systemRespiratory syndrome coronavirus 2Indirect cardiovascular complicationsCardiovascular side effectsAcute myocardial injurySyndrome coronavirus 2Coronavirus disease 2019Cardiovascular complicationsVenous thromboembolismMyocardial injuryCoronavirus 2Cardiovascular diseaseCardiovascular conditionsDisease 2019Severe diseaseSide effectsRapid triage